Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxinA
To the Editor: The role of neurocutaneous pathways in the pathogenesis of psoriasis has been suggested in cases of dermatomal improvement in psoriatic plaques following central or peripheral nerve damage [1] [2] [3] ; however, few studies have assessed the effect of nerve-targeting treatments, 4, 5 especially in plaque psoriasis. This study investigated the effect of onabotulinumtoxinA injections on psoriasis severity, epidermal nerve fiber (ENF) density, and expression of the neuropeptides substance P (SP) and calcitonin geneerelated peptide (CGRP).
In this single-center pilot study, 8 subjects (Fig 1,  A and B) with plaque psoriasis received a 1-time injection of onabotulinumtoxinA (Botox, Allergan, Inc, Irvine, CA) throughout a single target plaque (average units, 53; range, 25-98) and were followed for 10 weeks after the injection with assessment of their Psoriasis Area and Severity Index (PASI) score and Physician's Global Assessment (PGA) score and clinical photography. Punch biopsy specimens (diameter, 3 mm) obtained from lesional and perilesional skin 2 weeks before and 8 weeks after Reflectance confocal microscopy (RCM) images for 1 patient: image from an area of the patient's face randomized to the control (Q-switched alexandrite laseretreated) group before treatment (A) and at 2 weeks after treatment with a Q-switched alexandrite laser (B) and image from an area of the patient's face randomized to the experimental ( picosecond pulsed alexandrite laseretreated) group before treatment (C) and at 2 weeks after treatment (D). A and C, Arrows indicate the many high-refractive melanin particles the stratum spinosum. B, Arrow indicates the decrease in the number of melanin particles and spines of highly refractive dendritic cells in the stratum spinosum after treatment. D, Arrow indicates the decrease in the number of melanin particles in the stratum spinosum after treatment.
J AM ACAD DERMATOL injection were immunostained to visualize ENFs, SP and CGRP. Informed consent was obtained. The University of Minnesota Institutional Review Board approved this study (institutional review board approval No. 0808M45282).
For nerve quantification, 60-m-thick vertical sections of the biopsy specimen were immunostained with antibodies to the pan-neuronal marker protein gene product 9.5, type IV collagen (a basement membrane marker), and the neuropeptides SP and CGRP. Immunoreactive ENFs were imaged with spinning disk confocal microscopy and quantified with Neurolucida tracing software (MBF Bioscience, Williston, VT). Protein gene product 9.5elabeled ENFs crossing the dermoepidermal junction were expressed as ENFs/mm of basement membrane. SP-and CGRP-immunoreactive nerve fibers, expressed as SP or CGRP per section, were visualized and counted by using epifluorescent microscopy.
The analyses for PASI score, PGA score, ENF density, and SP-and CGRP-immunoreactive nerves were performed with use of mixed linear models with the restricted maximum likelihood method and JMP software (version 12 Pro; SAS Institute, Inc, Cary, NC).
The results are summarized in Figure 2 . Lesional samples had lower ENF density (lesional mean density, 4.6; perilesional density, 12.0 [P \ .01]) and higher SP-immunoreactive (lesional mean density, 9.2; perilesional density, 4.5 [P \.01]) and CGRP-immunoreactive (lesional mean density, 22.0; perilesional density, 10.6 [P ¼ .057]) nerve densities than the perilesional samples did. After injection, SP (P ¼ .061) and CGRP (P ¼ .053) immunoreactivity decreased in the lesional and perilesional samples whereas ENF density (P ¼ .10) increased. OnabotulinumtoxinA injections were associated with significantly decreased PASI and PGA scores (P \.01 for both). No serious adverse events or adverse effects directly related to the study drug were reported during this study. None of the subjects discontinued participation secondary to side effects.
There are several limitations to this study, including the small population size, predominance of males, lack of a placebo control, cost of onabotulinumtoxinA, and variance in body site of target plaque and average ENF and neuropeptide densities by body site.
In conclusion, the findings from this study support the idea that neurocutaneous pathways are altered in psoriasis and that onabotulinumtoxinA could be a potential treatment for recalcitrant, localized, psoriatic plaques. Its clinical effect of decreasing plaque severity may be mediated by decreasing SP-and CGRP-immunoreactive nerve expression and increasing ENF density. These injections were well tolerated by subjects. Future investigations evaluating the effect of onabotulinumtoxinA in a larger number of patients with recalcitrant plaque psoriasis are needed to confirm clinical efficacy and safety.
We are indebted to James Hodges, PhD, of the University of Minnesota School of Public Healthe Biostatistics Division, for his expertise in statistical analysis applied to this project, and to Dr James Andrews, DO, of Physical Medicine and Rehabilitation in Alexandria, Minnesota, for his initial observations that contributed to the development of this study. To the Editor: As a response to the increasing demand for dermatologic care and the geographic maldistribution of dermatologists, nonphysician clinicians (NPCs) (nurse practitioners and physician assistants) have become a significant component of the US dermatology workforce. 1,2 Recent studies have raised concerns that NPCs may at times deliver care at a higher cost. 3, 4 These concerns have intensified as private equity firms have entered the dermatology field and preferentially employed NPCs to increase profits. 5 The purpose of this study is to characterize recent trends in independent billing for dermatologic procedures by NPCs. Prior literature on NPCs in dermatology has been limited to studies of practice scope at single points in time. [1] [2] [3] We hypothesized that growth in common dermatologic services provided by NPCs would exceed that
